Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Sep 16:9:1136.
doi: 10.12688/f1000research.25553.1. eCollection 2020.

Green tea influence on iron overload in thalassemia intermedia patients: a randomized controlled trial

Hayder Al-Momen  1 , Hussein Khudhair Hussein  1 , Zaid Al-Attar  2 , Mohammed Jalal Hussein  1
Affiliations
Randomized Controlled Trial

Green tea influence on iron overload in thalassemia intermedia patients: a randomized controlled trial

Hayder Al-Momen et al. F1000Res. .

Abstract

Background: Although iron chelation therapies have been available for many years for thalassemia intermedia patients, iron accumulation remains the major cause of death. Therefore, the need for additional chelation options is in demand. This randomized controlled study aimed to understand the effects of green tea on iron balance in thalassemia intermedia patients. Methods: Using a random selection method, 141 thalassemia intermedia patients were initially screened for inclusion in this trial; only 68 patients included after applying exclusion criteria. Two equal groups were generated (n=34/group): green tea (three cups/day after meals) + usual treatment (deferasirox iron chelator and on demand blood transfusion); and control (only usual treatment). The study lasted for a period of 12 months. Patients failing to comply to the trial methodology were excluded, leaving a final total of 29 patients in the green tea group and 28 patients in the control group. Liver iron concentration, and serum ferritin were assessed at baseline and 12 months, while hemoglobin levels were assessed monthly. Results: At baseline, both groups were matched regarding general demographics. At 12 months, the net drop of liver iron concentration in the green tea group (7.3 mg Fe/g dry weight) was significantly higher than the control group (4.6 mg Fe/g dry weight) (p<0.05). This was also seen with serum ferritin; net reduction in green tea and control groups were 1289 ng/ml and 871 ng/ml, respectively (p<0.05). Hemoglobin levels were slightly higher in the green tea group compared with the control group, but this was not significant. Conclusions: Regular green tea consumption had a significant capability to improve iron deposition in thalassemia intermedia patients who already undergo deferesirox iron chelation therapy. Trial registration: UMIN-CTR Clinical Trials Registry, UMIN000040841 (retrospectively registered June 21, 2020).

Keywords: Deferasirox; Liver iron concentration; Serum ferritin; Thalassemia..

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Flowchart of participants.
Figure 2.
Figure 2.. Liver iron concentration (LIC) at the start and end of study period in the green tea (GT) and control groups.
Figure 3.
Figure 3.. Hemoglobin (Hb) levels in the green tea (GT) and control groups throughout the study (measured monthly).
See this image and copyright information in PMC

References

    1. Ben Salah N, Bou-Fakhredin R, Mellouli F, et al. : Revisiting beta thalassemia intermedia: past, present, and future prospects. Hematology. 2017;22(10):607–16. 10.1080/10245332.2017.1333246 - DOI - PubMed
    1. Asadov C, Alimirzoeva Z, Mammadova T, et al. : β-Thalassemia intermedia: a comprehensive overview and novel approaches. Int J Hematol. 2018;108(1):5–21. 10.1007/s12185-018-2411-9 - DOI - PubMed
    1. Yassin MA, Soliman AT, De Sanctis V, et al. : Final height and endocrine complications in patients with β-thalassemia intermedia: our experience in non-transfused versus infrequently transfused patients and correlations with liver iron content. Mediterr J Hematol Infect Dis. 2019;11(1):e2019026. 10.4084/MJHID.2019.026 - DOI - PMC - PubMed
    1. Vichinsky E: Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. Curr Med Res Opin. 2016;32(1):191–204. 10.1185/03007995.2015.1110128 - DOI - PubMed
    1. Al-Momen H: Iron chelation therapy in sickle cell/beta thalassemia syndrome, a 2 years’ extension study. Al-Kindy College Medical Journal. 2017;13(1):76–81. Reference Source

Publication types

Associated data

LinkOut - more resources